Etienne Dumont

TL;DR: Capecitabine is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil preferentially in tumors, which is explained to a great extent by the activity of TP in colorectal tumor tissue, (the enzyme responsible for the conversion of 5′-DFUR to 5-FU), which is approximately four times that in adjacent healthy tissue.

TL;DR: Data for gepotidacin from nonclinical studies, including in vitro activity, in vivo animal efficacy, and pharmacokinetic (PK) and Pharmacokinetic/pharmacodynamic (PK/PD) models that informed dose selection for phase III clinical evaluation are reviewed.

TL;DR: The pharmacokinetics of 9‐cis‐retinoic acid were linear over the dose range studied and adverse events observed were consistent with findings of other retinoids and included headache and xeroderma at high dose levels.

TL;DR: Gepotidacin was generally well‐tolerated, with no drug‐related serious adverse events reported, and these PK and safety data across a wide range of doses in healthy participants aged greater than or equal to 18 years support the development of gepotIDacin in further clinical studies.

TL;DR: A translational approach using in vitro pharmacokinetic/pharmacodynamic (PK/PD) and clinical data was used to select a gepotidacin dose for a phase III study.